Table 1 In vitro cytotoxicity phenotype (ATP depletion) and known in vivo cardiac safety liabilities of the test compounds
Drug | ATP depletion IC50 at 48 hrs (μM ± SE) | In vivo 5-day treatment (mg/kg) | Reported ECG abnormalities & arrhythmia | Reported structural cardiotoxicity | Primary pharmacology & indication |
|---|---|---|---|---|---|
Amiodarone | 12 ± 1.17 | 147 | Yes | No | Anti-arrhythmic |
Amitriptyline | 5.7 ± 0.67 | 160 | Yes | Yes | Tricyclic antidepressant |
Cyclosporine | 2.71 ± 0.92 | 350 | No | Yes | Immunosuppressive |
Dexamethasone | >300 | 1 | No | Yes | Glucocorticoid |
Dobutamine | 22.9 ± 0.83 | 43 | Yes | Yes | β1 agonist, inotropic |
Doxorubicin | 4.23 ± 0.52 | 3 | Yes | Yes | Cytotoxic Anti-neoplastic |
Loratadine | 39.5 ± 2.11 | 2000 | Yes | No | Anti-histaminic |
Mitoxantrone | 1.16 ± 0.47 | 2 | Yes | Yes | Cytotoxic Anti-neoplastic |
Terbutaline | >300 | 130 | Yes | Yes | β2 agonist |